Limits...
After the diabetes care trial ends, now what? A 1-year follow-up of the RxING study.

Al Hamarneh YN, Sauriol L, Tsuyuki RT - BMJ Open (2015)

Bottom Line: However, the sustainability and durability of such interventions beyond the research period is not known.Seventy-five patients were still taking insulin, with the average dose increasing from 31.1 units (SD 18.4) at study completion to 37.4 units (SD 30.8) (95% CI -13.3 to 0.88, p=0.085).Twelve months after completing the intervention, approximately half of the glycaemic control gains were lost.

View Article: PubMed Central - PubMed

Affiliation: EPICORE Centre, Department of Medicine, Faculty of medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus

Patient's enrolment and follow-up flow chart.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4538249&req=5

BMJOPEN2015008152F1: Patient's enrolment and follow-up flow chart.

Mentions: A total of 100 patients with poorly controlled type 2 diabetes were enrolled in the RxING study. Ninety-three patients completed the study, 86 (93%) of whom participated in the 12-month follow-up (figure 1).


After the diabetes care trial ends, now what? A 1-year follow-up of the RxING study.

Al Hamarneh YN, Sauriol L, Tsuyuki RT - BMJ Open (2015)

Patient's enrolment and follow-up flow chart.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4538249&req=5

BMJOPEN2015008152F1: Patient's enrolment and follow-up flow chart.
Mentions: A total of 100 patients with poorly controlled type 2 diabetes were enrolled in the RxING study. Ninety-three patients completed the study, 86 (93%) of whom participated in the 12-month follow-up (figure 1).

Bottom Line: However, the sustainability and durability of such interventions beyond the research period is not known.Seventy-five patients were still taking insulin, with the average dose increasing from 31.1 units (SD 18.4) at study completion to 37.4 units (SD 30.8) (95% CI -13.3 to 0.88, p=0.085).Twelve months after completing the intervention, approximately half of the glycaemic control gains were lost.

View Article: PubMed Central - PubMed

Affiliation: EPICORE Centre, Department of Medicine, Faculty of medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus